(MENAFN – TRACCS) Amman, Jordan (June 2021) -: Women’s health is changing and continuing with the launch of Organon (NYSE: OGN), the only global company of its size focused on women’s health prioritized. Women currently make up 47% of the Jordanian population that Organon seeks to empower, protect and support. With a vision of creating a better and healthier life for every woman every day by putting women at the center of all Organon activities, they have a comprehensive view of women’s health with the goal of going beyond reproductive health, to address the unique conditions for women, but also illnesses that disproportionately affect women or place a particularly heavy burden on them.
Organon Managing Director Ramy Koussa (Middle East, North Africa and Turkey) in Organon underlines the company’s vision: “As the MENAT region continues to grow and is expected to expand in the coming years, we recognize the need to focus on women-specific Health conditions and treatments that affect women’s daily lives. This introduction will not only change the health care of women, it will also create over 400 job vacancies in MENAT. With our know-how, our products and our technology in the area of women-specific diseases, we want to influence the change in the region and enable women to take care of their own health in order to lead a better life. ”
Organon’s executive team rang the opening bell on the New York Stock Exchange (NYSE) to celebrate the first day of active trading. Recognizing the need to listen and respond to women’s experiences to address women’s health challenges, Organon gathered voices from around the world to create the Wall of Voices, a multimedia installation outside the NYSE that shares powerful perspectives, voices and images.
Women everywhere are invited to take the “microphone” to add their voice to the digital “Wall of Voices” on HereForHerHealth.com.
Organon Jordan’s chief pharmacist Manal Dhainy said, “We’re not just here to make a living. We are here to bring the world a more generous, visionary, and finer life by striving to make every day better for every woman. Today is our opportunity to build the future every woman deserves by providing the right support, improving access to resources, and raising awareness of the importance of women’s health. We are all here for their health. ”
The three core pillars that guide Organon’s offerings in Jordan include:
• Biosimilars: Actively building a strong foundation by expanding the range of the offer to new regions while expanding through new collaborations and into new disease areas.
• Women’s Health: With more than 140 therapies researched by multiple companies in the women’s health industry, our goal is to create value by identifying and promoting the most promising opportunities for women.
• Established brands: Our portfolio of over 60 drugs spans multiple areas, including cardiovascular disease, respiratory disease, non-opioid pain management and dermatology. This diverse range of products and trusted brands are key drivers of Organon’s growth, allowing us to invest in new opportunities.
Organon has an international presence serving people in more than 140 markets and generating nearly 80% of its annual revenue of approximately $ 6.5 billion outside of the United States. Organon believes it is well positioned for organic growth in the low to mid single digits starting in 2021 as the foundation of its business. Their approach to innovation is guided by patient needs and the use of vast global capabilities in clinical development and patient safety with the greatest potential to impact women’s health. Sandy Milligan, Head of Organon Research & Development, said: “Women have been asked to accept and normalize their living conditions. Organon’s mission is to change that. We believe this approach will be very successful – we hope to discover the ability to detect disease earlier, change the course of disease or health condition, and ultimately improve the quality of life for women at all stages. ”
About Organon
Organon (NYSE: OGN) is a global healthcare company formed outside the United States and Canada through a spin-off from Merck known as MSD to focus on improving the health of women throughout their lives. For your health, the company has a portfolio of more than 60 drugs and products from a number of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and a stable franchise of established drugs, Organon’s products generate strong cash flows that will support investments in future growth opportunities in women’s health, including business development. In addition, Organon is pursuing opportunities to work with biopharmaceutical innovators who wish to commercialize their products by leveraging their size and presence in rapidly growing international markets.
Organon has a global footprint of significant size and geographic reach, world class commercial capabilities, and approximately 9,000 employees, headquartered in Jersey City, New Jersey.
For more information, visit us and connect with us on LinkedIn and Instagram.
MENAFN26062021003982000056ID1102347071
Disclaimer: MENAFN provides the information “as is” without any guarantee. We assume no responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this item, please contact the above provider.
source https://dailyhealthynews.ca/organon-jordan-launches-as-new-womens-health-company/
No comments:
Post a Comment